Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Research & Development (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Research & Development for 4 consecutive years, with $374012.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 4.26% to $374012.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 5.33% year-over-year, with the annual reading at $1.4 million for FY2025, 5.33% down from the prior year.
  • Research & Development for Q4 2025 was $374012.0 at bioAffinity Technologies, up from $330589.0 in the prior quarter.
  • The five-year high for Research & Development was $450612.0 in Q4 2022, with the low at $248419.0 in Q2 2022.
  • Average Research & Development over 4 years is $350696.6, with a median of $351255.5 recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 34.9% in 2023, then decreased 22.63% in 2025.
  • Over 4 years, Research & Development stood at $450612.0 in 2022, then dropped by 3.95% to $432818.0 in 2023, then decreased by 9.74% to $390658.0 in 2024, then dropped by 4.26% to $374012.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $374012.0, $330589.0, and $311372.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.